BRIEF—New biotech NImmune Biopharma buys assets from Landos

A new immunology company, NImmune Biopharma, has been launched to develop omilancor, NIM-1324, and the entire LANCL portfolio, which it has bought from Landos Biopharma.

The company has been set up by Josep Bassaganya-Riera, founder of Landos and the portfolio of assets which his new company has now acquired.

NImmune will move towards Phase III trials of omilancor in ulcerative colitis (UC), with the goal of exploring follow-on development in Crohn’s disease (CD) and psoriasis.

Dr Bassaganya-Riera said: “I am thrilled to regain ownership and leadership of the LANCL immunoregulatory therapeutic portfolio and look forward to continuing the development of these candidates at NImmune.”

He added: “Omilancor has the potential to impact the global inflammatory bowel disease (IBD) market as a safe and effective therapy, given the statistically significant clinical remission data it has produced in active disease UC patients as well as promising efficacy and safety results in CD patients.”